Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion

Hepatology

Volumn 57, Issue 3, 2013, Pages 934-943

  Yang, Hung Chih ^a,b   Chen, Chi Ling ^a   Shen, Yueh Chi ^a   Peng, Cheng Yuan ^c   Liu, Chun Jen ^a,b   Tseng, Tai Chung ^d   Su, Tung Hung ^a,b   Chuang, Wan Long ^e   Yu, Ming Lung ^e   Dai, Chia Yen ^e   Liu, Chen Hua ^a,b   Chen, Pei Jer ^a,b   Chen, Ding Shinn ^a,b   Kao, Jia Horng ^a,b,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; INTERFERON; RIBAVIRIN; VIRUS DNA;

ADULT; ARTICLE; BASAL CORE PROMOTER; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PRECORE PROMOTER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SEROCONVERSION; VIREMIA; VIRUS GENOME;

EID: 84984562157     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26121     Document Type: Article

References (29)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
3. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55: 2727-2734.
4. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
5. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007; 1: 415-430.
6. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009; 6: 453-462.
7. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25-137.
8. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591.
9. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Prevalence of HBV precore/core promoter variants in the United States. HEPATOLOGY 2003; 38: 619-628.
10. Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DK, Doutreloigne J, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002; 186: 1335-1338.
11. Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 2002; 40: 16-21.
12. Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol 2012; 56: 795-902.
13. Pang A, Yuen MF, Yuan HJ, Lai CL, Kwong YL. Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. J Hepatol 2004; 40: 1008-1017.
14. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143.
15. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
16. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. HEPATOLOGY 2000; 31: 716-725.
17. Fattovich G, McIntyre G, Thursz M, Colman K, Giuliano G, Alberti A, et al. Hepatitis B virus precore/core variation and interferon therapy. HEPATOLOGY 1995; 22: 1355-1362.
18. Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. HEPATOLOGY 1995; 21: 19-24.
19. Seo Y, Yoon S, Hamano K, Nakaji M, Yano Y, Katayama M, et al. Response to interferon-alpha in chronic hepatitis B with and without precore mutant strain detected by mutation site-specific assay. J Clin Gastroenterol 2004; 38: 460-464.
20. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011; 16: 629-637.
21. Duwe S, Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J Virol Methods 2008; 153: 134-141.
22. Lindstrom A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 2004; 42: 4788-4795.
23. Liu CJ, Lai MY, Chao YC, Liao LY, Yang SS, Hsiao TJ, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. HEPATOLOGY 2006; 43: 742-749.
24. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
25. Royo JL, Hidalgo M, Ruiz A. Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protoc 2007; 2: 1734-1739.
26. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. HEPATOLOGY 2003; 38: 1075-1086.
27. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298-1303.
28. Tur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. HEPATOLOGY 1992; 16: 1338-1342.
29. Liaw YF, Jia JD, Chan HLY, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. HEPATOLOGY 2011; 54: 1591-1599.